HOW IS COVAXIN DIFFERENT FROM EIGHT OTHER VACCINES.

What is the difference between Covaxin and eight other vaccines, And which vaccine is better? : Covid-19 cases have declined slightly worldwide. The reason for this is also the opinion that vaccination is being expressed by experts. Today (03 July 2021), more than 183.01 million people worldwide have been infected with the coronavirus. Kovid vaccines manufactured by various companies in India and abroad have significantly reduced the death rate.

When it comes to corona vaccines, contain and cover shields are manufactured in our country. Seven other vaccines are effective worldwide. Medicine manufacturers surveyed to determine the effective rate of the vaccine. Selected participants were divided into two groups, half of whom were given the original vaccine, and the other half were given an inactive drug.

1) COVAXIN: Hyderabad-based Bharat Biotech has developed the Kovacin vaccine, which makes up 77.8 percent of the vaccine against COVID-19. 65.2 percent against the new Delta variant. Bharat Biotech has released information on the results of Kovagjin Phase III Clinical Trials. The vaccine is said to be 77.8 percent effective against coronavirus. Dr. Krishna Ella, MD, Bharat Biotech MD, said 93.4 percent of those with severe Kovid symptoms and 65.2 percent were affected by the Delta variant. Kovaggin is said to prevent corona severe symptoms, resulting in reduced hospitalization.

covid vaccine india, corona vaccine, corona virus vaccine, first covid vaccine in inida

2) COVISHIELD: Covshield is the most widely used and available vaccine shield in the Telugu states of India. Of the two available vaccines, Covishield is more widely distributed than coaxing. The vaccine was developed by the University of Oxford in partnership with the British-Swedish organization AstraZeneca. The Pune-based serum is manufactured by the Institute of India (SII) in India. Studies on the efficacy of the Kovshield vaccine are extensive. According to AstraZeneca, after a preliminary analysis of the third stage clinical trials, the vaccine works with 76 percent efficacy against Kovid-19. With an inter-dose interval of 12 weeks or more, vaccine efficacy increased to 82 percent.

3) MODERNA: Moderna, a vaccine that came into emergency use in the United States a week after the Pfizer vaccine became available. According to Moderna's information to the Food and Drug Authority, the company provides 80.2% protection against the vaccine after the first dose and 95.6% after the second dose (this result applies to adults between the ages of 18-65 and only 86.4% for those over 65). Like the Pfizer vaccine, the real vaccine and placebo vaccine were given in two installments in the third phase trials simultaneously, over a period of 28 days. Will the immunity from the single vaccine continue? The company says it has become difficult to say. The Moderna vaccine also works effectively on alpha and beta variants. Research shows that it provides protection.

4) JOHNSON AND JOHNSON: Johnson received the Food and Drug Authority Emergency Consumption Permit on February 27, 2021. The Johnson & Johnson vaccine completely inactivates the single-dose delta variant. Experts say the vaccine lasts for about 8 months. Research shows that 85 percent of people who get the vaccine are not lethal to the virus.

It is the third Covid-19 vaccine to receive backing from the WHO, and the first requiring just a single injection.

5) ASTRAZENECA: According to a paper published by the Oxford-AstraZeneca Vaccine Company, the first dose is 64.1 percent effective, with a combined dose of 70.4 percent to 90 percent. The company says its effectiveness can be as high as 70 percent between 3 weeks and 9-12 weeks after the first vaccine is taken. This vaccine is 76% effective in reducing the risk of further 15 days of symptomatic disease and 100% against severe disease. The company claims that the vaccine is 85% effective in preventing COVID-19 in people over 65.

AstraZeneca COVID-19 vaccine vials. (IANS)

6) SINOPHARM: The vaccine is said to be effective against the Delta variant. Many countries, from Indonesia to Brazil, rely on China to vaccinate their people against COVID-19. Chinese vaccines work to reduce the symptoms of delta and the risk of serious cases. At least five types of vaccines from China are in the manufacturing stages. A vaccine made by Sinoform Company became available. The vaccine is said to be 79% effective after two doses. More than 10 lakh people have been vaccinated. Beyond China, countries such as Bahrain, Egypt, Jordan, Seychelles, and the United Arab Emirates use the vaccine. The United Arab Emirates‌ said in a press release that the vaccine is 86% effective.

Representational Image (IANS)

7) PFIGER-BIOTECH: The first vaccine in the world was Pfizer-BioMtech. The company reported clinical trial data on this vaccine. On December 11, Pfizer received the vaccine. In early May, Pfizer was more than 95 percent effective against death in protecting against the alpha variant (first discovered in the United Kingdom) and the beta variant (first found in South Africa) of the Pfizer-biotech vaccine. The company claims that the vaccine was 52% effective after the first dose and that 36,523 people were tested as part of the third phase of trials. Some were vaccinated twice over a 21-day period, while those without viral symptoms were given a placebo (vaccine). Of those who took the placebo vaccine, 82 were infected with the virus, while only 39 of those who took the actual vaccine were found to be infected with the virus. The Pfizer vaccine provides 95 percent protection after two doses. According to some doctors, the first dose of the vaccine is 90 percent effective in some people.

American pharma company Novavox has revealed that their corona vaccine works with 93 percent effectiveness. 8) NOVAVAX: The company claims that the vaccine works not only against COVID-19 but also against mutations found in Great Britain and against mutations that are effective in South Africa. It is said that the vaccine can fight all the variants found in the world. The company says the vaccine is safe to use and has very few side effects.

According to the results published in The Lancet, the companies claim that the Sputnik-V capacity is 91.6% after the 3rd phase trials. 9) SPUTNIK-V: The vaccine was developed by Sputnik-V in partnership with the Russian Direct Investment Fund (RDIF), the Gamaleya National Research Institute of Epidemiology and Microbiology in Moscow, Russia. It is being distributed in India by Dr. Reddy's Laboratories based in Hyderabad.

కంపెనీలు చెబుతున్నాయి.

This gives detailed information about Covaxin and 8 other major vaccines.